 Connection
Mulu Tesfay to Oncolytic Virotherapy
This is a "connection" page, showing publications Mulu Tesfay has written about Oncolytic Virotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.673 |
|
|
|
-
Tesfay MZ, Cios A, Cheng Z, Ferdous KU, Shelton RS, Mustafa B, Elliott NM, Raupach EA, Simoes CC, Miousse IR, Urbaniak A, Bauer MA, Siegel ER, Post SR, Chamcheu JC, Govindarajan R, Grdzelishvili VZ, Cannon MJ, Fernandez-Zapico ME, Basnakian AG, Chabu CY, Moaven O, Borad MJ, Nagalo BM. Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response. J Immunother Cancer. 2026 May 12; 14(5).
Score: 0.960
-
Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol. 2013 Apr; 87(7):3752-9.
Score: 0.381
-
Omolekan TO, Folahan JT, Tesfay MZ, Mohan H, Dutta O, Rahimian L, Ferdous KU, Ghavimi R, Cios A, Beng TK, Francis J, D'Auvergne O, Borad MJ, Kousoulas KG, DiGiuseppe S, Nagalo BM, Chamcheu JC. Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses. Front Immunol. 2025; 16:1618751.
Score: 0.228
-
Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Vesiculovirus neutralization by natural IgM and complement. J Virol. 2014 Jun; 88(11):6148-57.
Score: 0.103
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|